Valneva SE (VALN) Times Interest Earned (2021 - 2026)
Valneva SE (VALN) posted Times Interest Earned of $4.65 for Q1 2026, up 507.18% sequentially from -$1.14 in Q4 2025, and up 366.84% YoY from $1.0 in Q1 2025.
Powered by 
Analysis
Valneva SE (VALN) Times Interest Earned (2021 - 2026) Analysis & Trends
Valneva SE has reported Times Interest Earned for 6 years, with the latest figure at $4.65 in Q1 2026.
- Quarterly Times Interest Earned rose 366.84% year-over-year to $4.65 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.32 (up 8.22% YoY) and the FY2025 annual result came in at -$1.96, down 452.61% from the prior year.
- Times Interest Earned improved to $4.65 in Q1 2026 per VALN's latest filing, from -$1.14 in the prior quarter.
- Over five years, Times Interest Earned peaked at $37.92 in Q2 2022 and troughed at -$17.96 in Q3 2022.
- A 5-year average of $0.79 and a median of -$0.78 in 2023 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned soared 914.84% in 2022, then tumbled 52268.87% in 2024.
- Over 5 years, Times Interest Earned stood at -$1.74 in 2022, then soared by 55.3% to -$0.78 in 2023, then tumbled by 327.08% to -$3.31 in 2024, then surged by 65.52% to -$1.14 in 2025, then surged by 507.18% to $4.65 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered $4.65, -$1.14, and -$1.28 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 5.04 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.04 |
| Mar 31, 2026 | 4.65 |
| Dec 31, 2025 | -1.14 |
| Sep 30, 2025 | -1.28 |
| Jun 30, 2025 | 1.94 |
| Mar 31, 2025 | 1.00 |
| Dec 31, 2024 | -3.31 |
| Sep 30, 2024 | -0.42 |
| Jun 30, 2024 | 4.36 |
| Mar 31, 2024 | -9.68 |
| Dec 31, 2023 | 2.30 |
| Sep 30, 2023 | 6.17 |
| Jun 30, 2023 | 4.86 |
| Mar 31, 2023 | 3.25 |
| Dec 31, 2022 | 9.96 |
| Sep 30, 2022 | -17.96 |
| Jun 30, 2022 | 37.92 |
| Mar 31, 2022 | 3.90 |
| Dec 31, 2021 | -36.51 |
| Sep 30, 2021 | 40.86 |